Meeting
2023 ASCO Gastrointestinal Cancers Symposium
A phase I, first-in-human, open-label, dose escalation and expansion study of PT886 in adult patients with advanced gastric, gastroesophageal junction, and pancreatic adenocarcinomas.
Authors
Michael J. Overman
University of Texas MD Anderson Cancer Center, Houston, TX;
Michael J. Overman , Ramzi Melhem , Mariela A. Blum-Murphy , Claudia Ramos , Lina Petrosyan , Jack Li , Jessica K Perer , Hui Zou , Ming Wang , Harold M Wright
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05482893
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr TPS765)
DOI
10.1200/JCO.2023.41.4_suppl.TPS765
Abstract #
TPS765
Poster Bd #
Q1
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Safety of AK117, an anti-CD47 monoclonal antibody, in patients with advanced or metastatic solid tumors in a phase I study.
First Author: Hui Kong Gan
Poster
2023 ASCO Annual Meeting
Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study.
First Author: Funda Meric-Bernstam
Poster
2023 ASCO Annual Meeting
A phase I study of nelmastobart (hSTC810), an anti-BTN1A1 antibody, in patients with advanced solid tumors.
First Author: Soohyeon Lee
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.
First Author: Jing Huang